Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nosocomial Acinetobacter pneumonia.

Carlos M Luna1, Patricia K Aruj

  • 1Department of Internal Medicine, Pulmonary Diseases Division, Hospital de Clínicas, Universidad de Buenos Aires, Argentina. cymluna@advancedsl.com.ar

Respirology (Carlton, Vic.)
|November 8, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Research Priorities for Noninvasive Sampling of the Lower Respiratory Tract during Acute Respiratory Failure: An Official American Thoracic Society Workshop Report.

Annals of the American Thoracic Society·2025
Same author

Prevention of Aspiration: Oral Care, Antibiotics, Others.

Seminars in respiratory and critical care medicine·2024
Same author

[Updated recommendations for vaccination in adults with respiratory diseases. Argentine Association of Respiratory Medicine, 2023].

Medicina·2024
Same author

[Hamman's syndrome in SARS-CoV-2 pneumonia].

Medicina·2023
Same author

Correction: ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia.

Intensive care medicine·2023
Same author

ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia.

Intensive care medicine·2023
Same journal

Clinical Outcomes and Acute Exacerbation Incidence in Combined Pulmonary Fibrosis and Emphysema.

Respirology (Carlton, Vic.)·2026
Same journal

The SINFONIA Study: A Randomised Controlled Trial to Determine Feasibility and Effectiveness of Online Group Singing for People With COPD or ILD and Breathlessness.

Respirology (Carlton, Vic.)·2026
Same journal

Enhancing Asthma Management in Emergency Departments: New Approaches Are Vital for Effective Care.

Respirology (Carlton, Vic.)·2026
Same journal

High-Flow Nasal Oxygen in Early Home Pulmonary Rehabilitation for Exertional Hypoxaemia: A Pilot Randomised Feasibility Trial.

Respirology (Carlton, Vic.)·2026
Same journal

Contemporary Concise Review 2025: Asthma.

Respirology (Carlton, Vic.)·2026
Same journal

Early Intervention With Biologics for Asthma Remission: Promising or Premature?

Respirology (Carlton, Vic.)·2026
See all related articles

Acinetobacter spp. causes hospital-acquired pneumonia, especially in ventilated patients, due to its resistance and environmental persistence. Strict infection control and appropriate antibiotic treatment are crucial for managing outbreaks.

Area of Science:

  • Medical Microbiology
  • Infectious Diseases
  • Hospital Epidemiology

Background:

  • Acinetobacter spp., particularly A. baumannii, is a significant cause of nosocomial pneumonia in mechanically ventilated patients.
  • This bacterium exhibits intrinsic and acquired antimicrobial resistance and environmental persistence, leading to difficult-to-control outbreaks.
  • Nosocomial infections with Acinetobacter spp. are often linked to cross-transmission from the hospital environment or staff, rather than endogenous sources.

Purpose of the Study:

  • To highlight Acinetobacter spp. as a growing threat in hospital-acquired infections, particularly ventilator-associated pneumonia (VAP).
  • To discuss the contributing factors, clinical implications, and effective management strategies for Acinetobacter spp. VAP.
  • To emphasize the importance of infection control measures in preventing and managing outbreaks.

Related Experiment Videos

Main Methods:

  • Literature review and synthesis of existing data on Acinetobacter spp. epidemiology, resistance patterns, and clinical impact.
  • Analysis of risk factors associated with Acinetobacter spp. VAP, including hospitalization duration and prior antibiotic use.
  • Review of current antimicrobial treatment options and infection control strategies.

Main Results:

  • Acinetobacter spp. is the second most common Gram-negative cause of VAP, associated with high morbidity and mortality.
  • Risk factors for Acinetobacter spp. VAP include prolonged hospitalization, mechanical ventilation, and prior antibiotic exposure.
  • Effective antimicrobial agents include imipenem/cilastatin, amikacin, colistin, ampicillin/sulbactam, and tigecycline; monotherapy may suffice in uncomplicated cases.

Conclusions:

  • Strict infection control measures, including patient isolation, are paramount to prevent Acinetobacter spp. transmission and control outbreaks.
  • Differentiating between colonization and infection is critical for appropriate patient management.
  • The environmental persistence of Acinetobacter spp. poses a continuous challenge for healthcare facilities, necessitating robust infection prevention programs.